VBIO$0.54+1.71%
Valion Bio, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$1.16M
Float & O/S:2.15M / 2.16M
Inst Own:0.7%
DilutionScan read 50 of Valion Bio, Inc.'s SEC filings and found 28 warrant series, 4 convertibles, 2 ATM programs, 2 equity lines, 9 shelf registrations, 3 S-1 registrations and 10 completed offerings on file for VBIO. Analysis updated Oct 27, 2026.
Signal8 Summary
VBIO
Going-concern warning, near-zero cash, severe dilution
- Business
- WeakNo revenue, $2.1M cash vs $17.4M debt, going-concern warning
- Stock risk
- High$2.4M micro-cap, 1-for-25 split, shares +302% YoY
Snapshot
Valion Bio is a clinical-stage biotech with no revenue, a $7.9M operating loss and an $8.9M net loss in the latest fiscal year, and only $2.1M in cash against $17.4M of debt.
What's Happening Right Now
- : Valion filed a $100M shelf plus a $5M at-the-market offering, capped near $5M/year by SEC rules given its small market value, while its auditor flags going-concern doubt.
- : Registered $100.00M of securities for sale on Form S-3.
- : Nasdaq confirmed Valion regained compliance with the minimum bid price rule, closing out the delisting threat for now.
- : The latest 10-Q disclosed a $7.1M quarterly net loss, cash down to $2.1M, an explicit going-concern warning, and non-compliance with Nasdaq's minimum bid price rule.
- : Investor 3i, LP filed an amended 13D laying out up to $9M more funding tied to ousting CEO Michael Handley and installing its own nominees as Chairman and directors.
- : Raised $7.74M in gross proceeds through a private placement (PIPE), with warrants over 1.06M shares.
- : The board declared a 1-for-25 reverse stock split effective Aug 31, 2026 to regain Nasdaq compliance.
- : Raised $1.50M in gross proceeds through a private placement (PIPE), with warrants over 46K shares.
